TPCW
REGN icon

TD Private Client Wealth’s Regeneron Pharmaceuticals REGN Stock Holding History

TD Private Client Wealth’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$93.5K Sell
150
-20
-12% -$13.6K ﹤0.01% 784
2026
Q1 		$131K Buy
170
+1
+0.6% +$766 ﹤0.01% 720
2025
Q4 		$130K Buy
169
+15
+10% +$10.2K ﹤0.01% 731
2025
Q3 		$86.6K Buy
154
+46
+43% +$26K ﹤0.01% 773
2025
Q2 		$56.7K Sell
108
-19
-15% -$10.6K ﹤0.01% 825
2025
Q1 		$80.5K Sell
127
-44
-26% -$30.3K ﹤0.01% 732
2024
Q4 		$122K Buy
171
+15
+10% +$12.6K ﹤0.01% 686
2024
Q3 		$164K Buy
156
+7
+5% +$7.79K ﹤0.01% 644
2024
Q2 		$157K Sell
149
-8
-5% -$7.75K ﹤0.01% 611
2024
Q1 		$151K Buy
157
+20
+15% +$19K 0.01% 630
2023
Q4 		$120K Buy
137
+5
+4% +$4.12K ﹤0.01% 648
2023
Q3 		$109K Sell
132
-4
-3% -$3.14K ﹤0.01% 633
2023
Q2 		$97.7K Sell
136
-10
-7% -$7.71K ﹤0.01% 666
2023
Q1 		$120K Buy
146
+4
+3% +$3.02K 0.01% 621
2022
Q4 		$102K Sell
142
-7
-5% -$5.17K ﹤0.01% 624
2022
Q3 		$103K Buy
149
+33
+28% +$20.8K 0.01% 609
2022
Q2 		$68.6K Sell
116
-41
-26% -$26.7K ﹤0.01% 667
2022
Q1 		$110K Buy
157
+23
+17% +$14.6K ﹤0.01% 625
2021
Q4 		$84.6K Buy
134
+38
+40% +$23.4K ﹤0.01% 664
2021
Q3 		$58.1K Sell
96
-186
-66% -$115K ﹤0.01% 723
2021
Q2 		$158K Buy
282
+32
+13% +$16.2K 0.01% 555
2021
Q1 		$118K Buy
250
+83
+50% +$40.4K 0.01% 576
2020
Q4 		$80.7K Sell
167
-39
-19% -$21.1K ﹤0.01% 586
2020
Q3 		$115K Sell
206
-25
-11% -$15.2K 0.01% 514
2020
Q2 		$144K Sell
231
-18
-7% -$10.2K 0.01% 482
2020
Q1 		$122K Buy
249
+149
+149% +$61.5K 0.01% 473
2019
Q4 		$37.5K Buy
+100
New +$33.6K ﹤0.01% 643

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

TD Private Client Wealth's REGN Position: Q2 2026 in Review

TD Private Client Wealth reduced its Regeneron Pharmaceuticals (REGN) stake by 12% in Q2 2026, selling an estimated $13.6K and leaving 150 shares worth $93.5K. The position accounts for ﹤0.01% of the portfolio, ranked #784.

TD Private Client Wealth first reported a position in REGN in Q4 2019 and has held it in 27 quarters since. The position peaked at $164K in Q3 2024. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • TD Private Client Wealth held 150 shares of Regeneron Pharmaceuticals worth $93.5K as of Q2 2026.
  • TD Private Client Wealth sold 20 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $13.6K.
  • Regeneron Pharmaceuticals made up ﹤0.01% of TD Private Client Wealth's portfolio in Q2 2026, its #784 holding.
  • TD Private Client Wealth first reported a position in Regeneron Pharmaceuticals in Q4 2019 and has held it in 27 quarters since.
  • TD Private Client Wealth's Regeneron Pharmaceuticals position peaked at $164K in Q3 2024.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on TD Private Client Wealth's 13F filing for Q2 2026, filed 4 Aug 2026.